Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.96 USD
-0.04 (-1.33%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $2.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LPTX 2.96 -0.04(-1.33%)
Will LPTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LPTX
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
LPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
Other News for LPTX
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics announces $40 million private placement